scispace - formally typeset
K

Kai Singbartl

Researcher at Mayo Clinic

Publications -  103
Citations -  5183

Kai Singbartl is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Acute kidney injury & Sepsis. The author has an hindex of 34, co-authored 95 publications receiving 4374 citations. Previous affiliations of Kai Singbartl include RWTH Aachen University & University of Pittsburgh.

Papers
More filters
Journal ArticleDOI

Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation

TL;DR: Inhibition of platelet-neutrophil aggregation improved gas exchange, reduced neutrophil recruitment and permeability, and prolonged survival, and these findings may translate into improved clinical treatments for ALI.
Journal ArticleDOI

AKI in the ICU: definition, epidemiology, risk stratification, and outcomes

TL;DR: Experimental and small observational studies provide evidence that AKI impairs (innate) immunity and is associated with higher infection rates, and contrary to the conventional view, recent experimental and clinical data argue against renal ischemia-reperfusion as a sine qua non condition for the development of AKI.
Journal ArticleDOI

Urinary TIMP-2 and IGFBP7 as Early Biomarkers of Acute Kidney Injury and Renal Recovery following Cardiac Surgery

TL;DR: Urinary [TIMP-2]*[IGFBP7] serves as a sensitive and specific biomarker to predict AKI early after cardiac surgery and to predict renal recovery in patients who developed AKI.
Journal ArticleDOI

Noninvasive Ultrasound Imaging of Inflammation Using Microbubbles Targeted to Activated Leukocytes

TL;DR: It is concluded that noninvasive assessment of inflammation is possible by ultrasound imaging of microbubbles targeted to activated leukocytes by the presence of PS in the lipid shell.
Journal ArticleDOI

Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure

TL;DR: It is concluded that blocking P‐selectin even after onset of reperfusion protects mice from I/R‐induced ARF, suggesting potential therapeutic strategies aimed at blocking P-selectin.